- MindWalk Holdings Corp. announced a significant advancement in its AI-designed GLP-1 therapeutics program, introducing a **first-in-class dual-pathway regimen** for aging and longevity.  **[1715925_0001193125-25-210278_hyft-ex99_1.htm:0]** 
- The company's LensAI™ platform identified a novel connection between GLP-1 biology and a second, non-overlapping pathway, leading to the development of a **proprietary companion therapeutic** for co-administration with its GLP-1 receptor agonists.  **[1715925_0001193125-25-210278_hyft-ex99_1.htm:0]** 
- This strategic evolution positions MindWalk to target the high-growth longevity therapeutics market, which is projected to exceed **$60 billion by 2030**.  **[1715925_0001193125-25-210278_hyft-ex99_1.htm:0]** 
- MindWalk expects to provide updates on lead selection for the companion therapeutic and preclinical combination design parameters in the coming quarters.  **[1715925_0001193125-25-210278_hyft-ex99_1.htm:1]**

MindWalk Holdings Corp. Advances AI-Designed GLP-1 Program for Longevity

- MindWalk Holdings Corp. reported **record revenue of $7.6 million** for its first fiscal quarter of 2026, ended July 31, 2025, representing a **45% year-over-year increase**.  **[1715925_0001193125-25-202898_hyft-ex99_1.htm:0]** 
- The company's **gross margin expanded to 53%**, with **gross profit reaching $4.0 million**, and **net loss improved to $3.0 million** compared to $4.0 million in the prior year.  **[1715925_0001193125-25-202898_hyft-ex99_1.htm:0]** 
- MindWalk strengthened its balance sheet with a **cash balance of $5.0 million** at quarter-end, supplemented by **$16.1 million in net proceeds** from the divestiture of its Netherlands operations.  **[1715925_0001193125-25-202898_hyft-ex99_1.htm:0]** 
- The company completed its rebranding and advanced its dengue vaccine program into preclinical manufacturing, further validating its LensAI platform.  **[1715925_0001193125-25-202898_hyft-ex99_1.htm:0]**

MindWalk Holdings Corp. Reports Record Q1 2026 Revenue and Narrowed Losses

- MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) reported **revenue of $3.2 million** for the three months ended July 31, 2025, marking a **27.8% increase** compared to the same period in 2024, alongside a **net loss from continuing operations of $4.1 million**.  **[1715925_0001193125-25-202896_hyft-ex99_1.htm:2]** **[1715925_0001193125-25-202896_hyft-ex99_1.htm:7]** 
- The company completed the divestiture of its **IPA Europe B.V.** on **August 6, 2025**, for **$12 million USD**, generating **$11.7 million USD in net proceeds**.  **[1715925_0001193125-25-202896_hyft-ex99_2.htm:3]** **[1715925_0001193125-25-202896_hyft-ex99_1.htm:11]** **[1715925_0001193125-25-202896_hyft-ex99_2.htm:13]** 
- As of July 31, 2025, MindWalk had **$5.0 million in cash on hand** and stated that this amount is **insufficient to fund operations for at least one year**, raising **material uncertainties** regarding its ability to continue as a going concern without securing additional financing.  **[1715925_0001193125-25-202896_hyft-ex99_2.htm:3]** **[1715925_0001193125-25-202896_hyft-ex99_1.htm:7]** **[1715925_0001193125-25-202896_hyft-ex99_1.htm:11]** 
- Management identified a **material weakness** in internal controls over financial reporting as of July 31, 2025, attributed to insufficient resources for complex technical accounting issues, with remediation efforts ongoing.  **[1715925_0001193125-25-202896_hyft-ex99_1.htm:13]**

MindWalk Holdings (HYFT)